Dupont Capital Management Corp Zai Lab LTD Transaction History

Dupont Capital Management Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 26, 2022	SELL	$23.14 - $49.68 $97,581 - $209,500	-4,217 Closed	0 $0
Q1 2022 Apr 27, 2022	SELL	$27.77 - $64.4 $27,770 - $64,400	-1,000 Reduced 19.17%	4,217 $185,000
Q4 2021 Jan 31, 2022	BUY	$54.9 - $105.21 $16,689 - $31,983	304 Added 6.19%	5,217 $328,000
Q3 2021 Nov 03, 2021	SELL	$105.0 - $178.37 $59,535 - $101,135	-567 Reduced 10.35%	4,913 $518,000
Q1 2021 Apr 29, 2021	BUY	$126.27 - $191.71 $691,959 - $1.05 Million	5,480 New	5,480 $731,000
Q2 2020 Jul 24, 2020	SELL	$48.82 - $82.53 $382,358 - $646,374	-7,832 Closed	0 $0
Q1 2020 Apr 29, 2020	SELL	$39.1 - $62.9 $96,225 - $154,796	-2,461 Reduced 23.91%	7,832 $403,000
Q4 2019 Jan 27, 2020	BUY	$29.79 - $43.06 $306,628 - $443,216	10,293 New	10,293 $428,000

121

46.7M

223K

588K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.66B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of Dupont Capital Management Corp, based on Form 13F filings with the SEC.

Stay updated on Dupont Capital Management Corp with notifications on news.